SQZ PBMC HBV
Alternative Names: SQZ-PBMC-HBVLatest Information Update: 29 Mar 2021
Price :
$50 *
At a glance
- Originator SQZ Biotech
- Class Hepatitis B vaccines; T lymphocyte cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 24 Mar 2021 Preclinical trials in Hepatitis B in USA (unspecified route)
- 24 Mar 2021 SQZ Biotech announces intention to submit IND application to the US FDA for Hepatitis B infections in 2022
- 31 Dec 2020 Pharmacodynamics data from a preclinical studies in Hepatitis B infection released by SQZ Biotech